Owkin Enters Into Agreement to Build Innovative Methods With the Potential to Enhance AI-Enabled External Control Arms
September 20, 2021
NEW YORK, September 15, 2021 (Newswire.com) – Owkin, a startup pioneering Federated Learning and AI technologies for medical research and clinical development, announces an agreement with Actelion Pharmaceuticals Ltd., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to augment clinical trials with advanced machine learning methodologies.
Read the source article at Newswire
2021-09-15 14:00:00
